Regulation of leukotriene and platelet-activating factor synthesis in human alveolar macrophages

被引:9
|
作者
Shamsuddin, M [1 ]
Chen, E [1 ]
Anderson, J [1 ]
Smith, LJ [1 ]
机构
[1] Northwestern Univ, Sch Med, Div Pulm, Vet Affairs Lakeside Med Ctr, Chicago, IL 60611 USA
来源
关键词
D O I
10.1016/S0022-2143(97)90111-6
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
It has been suggested that phospholipase A(2) (PLA(2)) contributes to the regulation of leukotriene (LT) and platelet-activating factor (PAF) synthesis by controlling the release of their precursors, arachidonic acid (AA) and lysophosphatidylcholine (lysoPC), from membrane phospholipids. In rat alveolar macrophages (AMs), PLA(2) appears to have a major role in LT synthesis but a more limited role in PAF synthesis. The present study was designed to define the role of PLA(2) in LT and PAF synthesis In human AMs and determine whether differences exist between AMs obtained from normal subjects and those from patients with asthma. In the normal subjects, the calcium Ionophore A23187 (Gal) increased AM PAF synthesis (percent incorporation of tritiated acetate) by 135% (p < 0.01) and LTB4 synthesis 88-fold (p < 0.001). Phorbol myristate acetate (PMA) had little effect alone, but it had a synergistic effect with Gal, increasing PAF synthesis by 466% and LTB4 synthesis to 229-fold above the control values (p < 0.001 for both). Po 25-4331, a combined cytosolic (c) and secretory (s) PLA(2) inhibitor, had little effect on the Gal-stimulated PAF synthesis, but it completely blocked the effect of PMA. It also blocked the Gal-and Gal + PMA-stimulated LTB4 synthesis. AACOCF(3), a cPLA(2) inhibitor, had no effect on either Gal or Cal+PMA-stimulated PAF synthesis. It reduced LTB4 synthesis, but it did so less effectively than Po 25-4331. CoA-independent transacylase (CoAl-TA) activity in the AMs increased after stimulation and exposure to Po 25-4331. SK&F 45905, a CoAl-TA inhibitor, reduced stimulated PAF synthesis by 30% to 40%. Patients with asthma had similar results except that cPLA(2) had a greater role in stimulated LTB, synthesis. These data indicate that PLA(2) plays a direct role in human AM LT synthesis; both the cytosolic and secretory forms contribute to LT synthesis; PLA(2) appears to have a more limited role in PAF synthesis, although it mediates the synergistic effect of PMA, probably via sPLA(2); and CoAl-TA contributes to PAF synthesis during PLA(2) inhibition. With the exception of the greater role for cPLA(2) in stimulated LTB4 synthesis in the patients with asthma, the contributions of PLA(2) and CoAl-TA to AM LT and PAF synthesis appear to be similar in normal subjects and patients with asthma.
引用
收藏
页码:615 / 626
页数:12
相关论文
共 50 条
  • [31] Regulation of platelet-activating factor receptor gene expression in vivo by endotoxin, platelet-activating factor and endogenous tumour necrosis factor
    Wang, H
    Tan, XD
    Chang, H
    GonzalezCrussi, F
    Remick, DG
    Hsueh, W
    BIOCHEMICAL JOURNAL, 1997, 322 : 603 - 608
  • [32] PLATELET-ACTIVATING FACTOR
    WYKLE, RL
    OFLAHERTY, JT
    THOMAS, MJ
    METHODS IN ENZYMOLOGY, 1988, 163 : 44 - 54
  • [33] PLATELET-ACTIVATING FACTOR
    MARTIN, J
    LANCET, 1988, 2 (8626-7): : 1486 - 1486
  • [34] Inhibitory effect of azelastine hydrochloride on synthesis and release of platelet activating factor from human alveolar macrophages
    Shindo, K
    Machida, M
    Hirai, Y
    Fukumura, M
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1997, 57 (06): : 561 - 566
  • [35] PLATELET-ACTIVATING FACTOR
    CUSACK, NJ
    NATURE, 1980, 285 (5762) : 193 - 193
  • [36] INVOLVEMENT OF EICOSANOIDS IN PLATELET-ACTIVATING FACTOR-INDUCED MODULATION OF ADENYLYL CYCLASE ACTIVITY IN ALVEOLAR MACROPHAGES
    BEUSENBERG, FD
    VANSCHAIK, A
    VANAMSTERDAM, JGC
    BONTA, IL
    JOURNAL OF LIPID MEDIATORS, 1991, 3 (03): : 301 - 309
  • [37] PLATELET-ACTIVATING FACTOR
    PINCKARD, RN
    HOSPITAL PRACTICE, 1983, 18 (11): : 67 - 76
  • [38] Platelet-activating factor
    Owen, John S.
    Thomas, Michael J.
    Wykle, Robert L.
    LIPIDOMICS AND BIOACTIVE LIPIDS: LIPIDS AND CELL SIGNALING, 2007, 434 : 105 - 116
  • [39] Platelet-activating factor and human thyroid cancer
    Denizot, Y
    Chianéa, T
    Labrousse, F
    Truffinet, W
    Delage, M
    Mathonnet, M
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (01) : 31 - 40
  • [40] PLATELET-ACTIVATING FACTOR
    VALONE, FH
    WESTERN JOURNAL OF MEDICINE, 1989, 150 (03): : 334 - 334